Shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) have earned a consensus rating of “Hold” from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $51.00.
A number of research firms have issued reports on VIR. Morgan Stanley started coverage on Vir Biotechnology in a research note on Friday, September 9th. They issued an “underweight” rating and a $15.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $125.00 price target on shares of Vir Biotechnology in a research report on Thursday, July 14th. Barclays reduced their price target on Vir Biotechnology to $67.00 in a research report on Monday, August 15th. Finally, SVB Leerink initiated coverage on Vir Biotechnology in a research report on Wednesday, September 14th. They set an “outperform” rating and a $40.00 price target for the company.
Insider Buying and Selling at Vir Biotechnology
In other Vir Biotechnology news, Director Saira Ramasastry sold 5,000 shares of the firm’s stock in a transaction on Monday, July 11th. The stock was sold at an average price of $30.00, for a total value of $150,000.00. Following the sale, the director now owns 8,092 shares of the company’s stock, valued at approximately $242,760. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, major shareholder Endurance (Cayman) Ltd Svf sold 122,564 shares of the firm’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $27.99, for a total transaction of $3,430,566.36. Following the sale, the insider now owns 22,094,080 shares of the company’s stock, valued at approximately $618,413,299.20. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Saira Ramasastry sold 5,000 shares of the firm’s stock in a transaction on Monday, July 11th. The shares were sold at an average price of $30.00, for a total value of $150,000.00. Following the sale, the director now directly owns 8,092 shares in the company, valued at approximately $242,760. The disclosure for this sale can be found here. In the last quarter, insiders have sold 150,479 shares of company stock valued at $4,122,905. 22.40% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the stock. Massachusetts Financial Services Co. MA raised its position in Vir Biotechnology by 0.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 105,665 shares of the company’s stock worth $2,691,000 after purchasing an additional 537 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Vir Biotechnology by 127.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock valued at $25,000 after purchasing an additional 560 shares during the last quarter. Handelsbanken Fonder AB boosted its stake in shares of Vir Biotechnology by 5.4% in the 1st quarter. Handelsbanken Fonder AB now owns 11,800 shares of the company’s stock worth $303,000 after buying an additional 600 shares during the last quarter. US Bancorp DE boosted its stake in shares of Vir Biotechnology by 175.1% in the 2nd quarter. US Bancorp DE now owns 982 shares of the company’s stock worth $25,000 after buying an additional 625 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in shares of Vir Biotechnology by 6.8% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 9,983 shares of the company’s stock worth $257,000 after buying an additional 635 shares during the last quarter. 64.55% of the stock is owned by institutional investors.
Vir Biotechnology Stock Performance
Shares of VIR stock opened at $21.34 on Friday. The stock’s 50 day simple moving average is $23.67 and its 200 day simple moving average is $24.33. The company has a market capitalization of $2.83 billion, a price-to-earnings ratio of 2.66 and a beta of -0.06. Vir Biotechnology has a twelve month low of $18.05 and a twelve month high of $58.00.
Vir Biotechnology (NASDAQ:VIR – Get Rating) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.41). The firm had revenue of $40.60 million for the quarter, compared to analyst estimates of $211.14 million. Vir Biotechnology had a return on equity of 68.86% and a net margin of 52.29%. Vir Biotechnology’s revenue for the quarter was down 77.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.46 EPS. On average, analysts forecast that Vir Biotechnology will post 3.04 EPS for the current fiscal year.
Vir Biotechnology Company Profile
(Get Rating)
Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vir Biotechnology, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Vir Biotechnology wasn’t on the list.
While Vir Biotechnology currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Originally published at Melbourne News Vine
No comments:
Post a Comment